Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

Authors

Ami V Desai, University of Chicago
Karen Gauvain, Washington University School of Medicine in St. Louis
Amy E Armstrong, Washington University School of Medicine in St. Louis
et al.

Journal

Neuro-Oncology

Publication Date

10-3-2022

Volume

24

Issue

10

First Page

1776

Last Page

1789

Document Type

Open Access Publication

DOI

10.1093/neuonc/noac087

Rights and Permissions

Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Janet Yoon, Brian D Weiss, Mohamed S Abdelbaki, Amy E Armstrong, Thomas Cash, Christine A Pratilas, Nadège Corradini, Lynley V Marshall, Mufiza Farid-Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses-Lorente, Alison Cardenas, Katherine E Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox, Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG), Neuro-Oncology, Volume 24, Issue 10, October 2022, Pages 1776–1789, https://doi.org/10.1093/neuonc/noac087. © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

Recommended Citation

Desai, Ami V; Gauvain, Karen; Armstrong, Amy E; and et al., "Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)." Neuro-Oncology. 24, 10. 1776 - 1789. (2022).
https://digitalcommons.wustl.edu/oa_4/632